Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC101 TIL therapy in advanced solid tumors
NCT05417750Phase 1Completed
- Sponsor
- Juncell Therapeutics
- Start
- Oct 2022
- Primary completion
- Apr 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nolgileucel in melanoma, Cervical Cancer (CC), head and neck squamous cell carcinoma (HNSCC) and 2 more (5 cohorts), sponsored by Juncell Therapeutics. Primary endpoints: Maximal Tolerance Dose at 28 days, Dose Limiting Toxicity at 28 days and 1 more. Started Oct 2022; status: completed.
02
Drugs
nolgileucel
03
Conditions
melanomaCervical Cancer (CC)head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)breast cancer
Beyond the preview
Go deeper on NCT05417750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05417750.